(IN BRIEF) AstraZeneca is set to unveil promising data at the 65th American Society of Hematology (ASH) Annual Meeting, highlighting its expanding hematology pipeline and the enduring effectiveness of Calquence in treating chronic lymphocytic leukemia (CLL). The presentation includes six-year … Read the full press release
(IN BRIEF) AstraZeneca has introduced Evinova, a groundbreaking venture poised to become a leader in digital health solutions, catering to the needs of healthcare professionals, regulators, and patients. Backed by AstraZeneca and strategically collaborating with Parexel and Fortrea, Evinova is … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Cristina Duran, digital health solutions, digital technology, Evinova, Fortrea, Healthcare, Parexel, partnership, Pascal Soriot, sustainability
(IN BRIEF) AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has gained approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer possessing specific … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, Breast Cancer Treatment, Dave Fredrickson, Faslodex, Komal Jhaveri, Truqap, US FDA
(IN BRIEF) AstraZeneca has reported positive high-level results from the EMERALD-1 Phase III trial, demonstrating that its drug Imfinzi (durvalumab), in combination with transarterial chemoembolisation (TACE) and bevacizumab, significantly improves progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC) eligible … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, bevacizumab, Dr. Riccardo Lencioni, EMERALD-1, HCC, Imfinzi, Imfinzi Combination Therapy, Liver Cancer Treatment, Phase III Trial, Susan Galbraith, TACE
(IN BRIEF) AstraZeneca and Eccogene have signed an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) designed for the treatment of obesity, type-2 diabetes, and other cardiometabolic conditions. Initial results from the Phase … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Cardiometabolic Conditions, ECC5004, Eccogene, Exclusive License, Jingye Zhou, Obesity, Oral GLP-1RA, partnership, Sharon Barr, sustainability, type 2 diabetes
(IN BRIEF) AstraZeneca has entered into a collaboration and investment agreement with biotech firm Cellectis to fast-track the development of cutting-edge therapeutics in areas such as oncology, immunology, and rare diseases. This partnership will leverage Cellectis’ gene editing technologies and … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, André Choulika, AstraZeneca, Cellectis, gene therapy, immunology, Marc Dunoyer, oncology, partnership, rare diseases, sustainability
(IN BRIEF) AstraZeneca’s Supplemental Biologics License Application (sBLA) seeking approval for a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray flu vaccine, has been accepted for review by the US Food and Drug Administration (FDA). If approved, … Read the full press release
(IN BRIEF) AstraZeneca and Daiichi Sankyo have received European Union (EU) approval for their drug Enhertu as a monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in adult patients with activating HER2 mutations who require systemic therapy … Read the full press release
Posted in Business, Environment, European Union, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Daiichi Sankyo, Dave Fredrickson, Enhertu, EU approval, HER2-Mutant, Ken Keller, lung cancer, Martin Reck, monotherapy, NSCLC, partnership, sustainability
(IN BRIEF) Soliris (eculizumab) has received approval in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). This makes Soliris the first and only complement inhibitor approved for NMOSD … Read the full press release
(IN BRIEF) AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic epidermal … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, chemotherapy, EGFR, FLAURA2, lung cancer, osimertinib, Susan Galbraith, Tagrisso, Treatment USA
(IN BRIEF) AstraZeneca has revealed the eight winners of its 2023 R&D Postdoctoral Challenge, an initiative that supports early-career scientists in pursuing their innovative research proposals. Unlike traditional industry postdoctoral programs, this unique challenge allows researchers from around the world … Read the full press release
(IN BRIEF) AstraZeneca is set to present new data at the 12th annual IDWeek conference, emphasizing the role of long-acting antibodies and vaccines in safeguarding at-risk individuals from common infectious respiratory diseases. The company will share 15 abstracts, including oral … Read the full press release
(IN BRIEF) Alexion, a subsidiary of AstraZeneca Rare Disease, is set to present new data at the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, Alize Vives, Anna Francis, AQP4, AstraZeneca, Christophe Hotermans, ECTRIMS-ACTRIMS Meeting, effectiveness, Jin Nakahara, Justin Lee, Michael Levy, multiple sclerosis, NMOSD, Rare Neurological Disorder, rituximab, Sami Fam, Soliris, treatment, Ultomiris, Viktoria Papp
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, breast cancer, cancer treatments, datopotamab deruxtecan, Dave Fredrickson, DESTINY-PanTumor02, DUO-E, ESMO Congress, FLAURA2, gastrointestinal cancer, Imfinzi, lung cancer, MATTERHORN, Phase III Trials, Susan Galbraith, Tagrisso, TROPION-Breast01, TROPION-Lung01
(IN BRIEF) Alexion, in collaboration with AstraZeneca Rare Disease, has finalized an agreement to acquire a collection of preclinical rare disease gene therapy programs and related technologies from Pfizer Inc. This strategic move combines the expertise of Alexion and AstraZeneca … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged acquisition, Adrian Kemp, Alexion, AstraZeneca, AstraZeneca Rare Disease, gene therapy, genomic medicine, partnership, Pfizer
(IN BRIEF) AstraZeneca’s Head of Global Media Relations, Jacob Lund, has been chosen as the new Head of Corporate Communication & Sustainability and a member of the Executive Leadership Team at Investor. With a decade of experience at AstraZeneca, holding … Read the full press release
(IN BRIEF) AstraZeneca is advancing its lung cancer portfolio at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer. The company is aiming to have an AstraZeneca medicine for over half of all … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, Dave Fredrickson, FLAURA2, IASLC Conference 2023, Lung Cancer Treatments, Susan Galbraith, Tagrisso (osimertinib), therapy, World Conference on Lung Cancer (WCLC)
(IN BRIEF) AstraZeneca’s new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review by the US FDA for the treatment of advanced breast cancer. The NDA is being reviewed under Project Orbis, which … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged 2022 San Antonio Breast Cancer Symposium, AstraZeneca, breast cancer, CAPItello-291 Phase III, capivasertib, CDK4/6 inhibitors, endocrine therapies, Faslodex, FDA, Food and Drug Administration, fulvestran, hormone receptor, metastatic breast cancer, NDA, New Drug Application, Priority Review, Susan Galbraith, The New England Journal of Medicine
(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, autoimmune disease, cell therapies, Foxp3 Phenotype Lock, Iain McGill, IBD, IND, inflammatory bowel disease, Investigational New Drug, Mene Pangalos, multi-modular Treg cell therapy, Quell, Quell Therapeutics, T-regulator, T-regulatory cell engineering, T1D, Treg, type 1 diabetes
(IN BRIEF) AstraZeneca is set to present data on its Vaccines and Immune Therapies portfolio at the European Congress of Clinical Microbiology & Infectious Diseases. Among the data to be presented will be details on the progress of AstraZeneca’s Vaccines … Read the full press release
Posted in Business, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, AZD3152, Beyfortus, ECCMID 2023, Evusheld, Immune Therapies, Iskra Reic, vaccines, Vaxzevria
(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research Annual Meeting. A total of 70 presentations will be given, including a plenary presentation on the AEGEAN Phase III … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, AZD5335, AZD9592, early-stage, Imfinzi, lung cancer, oncology, Susan Galbraith, treatment
(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab) in the United States. Under the new arrangements, Sanofi will have full commercial control of nirsevimab in the U.S. Sanofi … Read the full press release
Posted in Business, France, Healthcare, Industrial, Management, News, Pharma & Biotech
Tagged AstraZeneca, Beyfortus, commercialization, contractual agreements, nirsevimab, partnership, Sanofi, Sobi, USA
(ACTUALITÉ EN BREF) The Co-operative Group Limited a annoncé qu’Adrian Marsh rejoindrait la société en tant qu’administrateur non exécutif indépendant et président du comité des risques et d’audit. Marsh prend sa retraite de son poste de directeur financier du groupe … Read the full press release
(IN BRIEF) The Co-operative Group Limited has announced that Adrian Marsh will join the company as an Independent Non-Executive Director and Chair of the Risk and Audit Committee. Marsh is retiring from his role as Group Finance Director at FTSE … Read the full press release
(ACTUALITÉ EN BREF) AstraZeneca a lancé le Défi postdoctoral R&D 2023, qui invite les étudiants en dernière année de médecine et/ou de doctorat et les chercheurs postdoctoraux du monde entier à soumettre leurs propres propositions de recherche. L’initiative est conçue … Read the full press release
(IN BRIEF) AstraZeneca has launched the 2023 R&D Postdoctoral Challenge, which invites final-year MD and/or PhD students and postdoctoral researchers from around the world to submit their own research proposals. The initiative is designed to promote diversity of thought and … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of its acquisition of Neogene Therapeutics Inc. Neogene is a global clinical-stage biotechnology company that specializes in the discovery, … Read the full press release
(COMUNICADO DE PRENSA) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueca farmacéutica y de biotecnología, ha anunciado la finalización de su adquisición de Neogene Therapeutics Inc. Neogene es una compañía global de biotecnología en etapa clínica que … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced that its drug Tezspire (tezepelumab) has been given the green light for self-administration by the European Medicine Agency’s Committee for Medicinal … Read the full press release
Posted in European Union, Healthcare, News, Pharma & Biotech, Science, Sweden, Technology, United Kingdom
Tagged allergic, asthma, asthma biologic, AstraZeneca, convenient pre-filled pen, EMA, eosinophilic, EU approval, Mene Pangalos, Professor Ian Pavord, self-administration, severe asthma patients, tezepelumab, Tezspire, University of Oxford
(COMUNICADO DE PRENSA) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueco-farmacéutica y biotecnológica, ha anunciado que su fármaco Tezspire (tezepelumab) ha recibido luz verde para la autoadministración por parte del Comité de Medicamentos de Uso Humano (CHMP) … Read the full press release
Posted in European Union, Healthcare, News, Pharma & Biotech, Science, Sweden, Technology, United Kingdom
Tagged alérgica, aprobación de la UE, asma, asma biológica, AstraZeneca, autoadministración, EMA, eosinofílica, Mene Pangalos, pacientes con asma grave, pluma precargada conveniente, profesor Ian Pavord, tezepelumab, Tezspire, Universidad de Oxford
(PRESS RELEASE) CAMBRIDGE, 2-Nov-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced fully funded postdoctoral research positions for the six winners at its R&D Postdoctoral Challenge announced earlier this year. The research positions … Read the full press release
(PRESSEMITTEILUNG) CAMBRIDGE, 2-Nov-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), ein britisch-schwedisches multinationales Unternehmen Pharma- und Biotechnologieunternehmen, hat voll finanzierte Postdoktoranden-Forschungsstellen für die sechs Gewinner in seinem R&D Postdoctoral Challenge früher in diesem Jahr angekündigt. Die Forschungspositionen werden für zwei Jahre … Read the full press release
Posted in Education, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Biopharmazie, Prof. Sir Mene Pangalos, R&D Postdoctoral Challenge
El desafío tiene como objetivo ayudar al descubrimiento de avances transformadores en las áreas de enfermedades centrales de AstraZeneca. Las propuestas exitosas asegurarán puestos de investigación posdoctorales totalmente financiados (COMUNICADO DE PRENSA) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), … Read the full press release
The challenge aims at helping the discovery of transformative breakthroughs across AstraZeneca’s core disease areas Successful proposals will secure fully funded postdoctoral research positions (PRESS RELEASE) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology … Read the full press release
(COMMUNIQUÉ DE PRESSE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON : AZN), une multinationale pharmaceutique et biotechnologique anglo-suédoise , a annoncé l’approbation par l’Union européenne (UE) de son médicament Saphnelo (anifrolumab) en tant que traitement d’appoint pour le traitement des patients … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced an European Union (EU) approval for its Saphnelo (anifrolumab) medicine as an add-on therapy for the treatment of adult patients with … Read the full press release
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, amyloid fibril deposits, amyloidosis, AstraZeneca, ATTR-CM, cardiomyopathies, Heart, heart failure, human monoclonal antibody, licence agreement, Marc Dunoyer, misfolded transthyretin, Neurimmune AG, NI006, rare disease, transthyretin amyloid cardiomyopathy
(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Aclidinium bromide, Adrian Kemp, Almirall S.A., AstraZeneca, biopharmaceutical, Bretaris, Brimica, Chronic obstructive pulmonary disease, Covis Pharma, Covis Pharma Group, dry powder inhaler, Duaklir, Eklira, formoterol, Genuair, inhaled respiratory medicines, LABA, LAMA, muscarinic antagonist, Tudorza
Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced it sold the global rights of its chronic obstructive … Read the full press release
Posted in Business, Healthcare, Management, News, Pharma & Biotech
Tagged Aclidinium bromide, Almirall S.A., Alvesco, AstraZeneca, biopharmaceutical, Bretaris, Chronic obstructive pulmonary disease, COPD, Covis Pharma, Covis Pharma Group, Duaklir, Eklira, formoterol, Genuair, Genuair device, global rights, inhaler, LABA, LAMA, long-acting beta2-agonist, long-acting muscarinic antagonist, medicines, Omnaris, Pressair, respiratory medicines, rights, Tudorza, Zetonna
(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its rare diseases arm Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences, Inc., a Clinical Stage … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abnormal antibody, acquisition, AL amyloidosis, Alexion, amyloids, AstraZeneca, bone marrow, CAEL-101, Caelum Biosciences, Cardiac Amyloid Reaching for Extended Survival, CARES Phase III clinical programme, defective plasma cells, IIIb disease, immunoglobulin, light chain (AL) amyloidosis, mAb, Marc Dunoyer, Mayo stage IIIa, monoclonal antibody, rare disease
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?